Modality
mAb
MOA
PCSK9i
Target
SOS1
Pathway
PI3K/AKT
ASMCLIPF
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
Nov 2020
→ Jul 2030
Phase 2Current
NCT04127495
1,618 pts·AS
2020-11→2030-07·Not yet recruiting
1,618 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-074.3y awayPh3 Readout· AS
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Not yet…
Catalysts
Ph3 Readout
2030-07-07 · 4.3y away
AS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04127495 | Phase 2/3 | AS | Not yet recr... | 1618 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 |